Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 may slow disease progression and decrease the severity of symptoms
If you meet the following three criteria, you may be eligible for the study. Participate! Help us!
- Positive in COVID-19
- Age ≥ 50 years
If you have any questions, please contact the researchers by calling 634 755 945 or sending an e-mail to firstname.lastname@example.org.
Description of the Study:
- Title: Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients.
- Principal Investigators: Oriol Mitjà and Bonaventura Clotet.
- Centers of Implementation: Centers in the health region of Bages-Berguedà, Barcelona, Metropolitan South and Metropolitan North. In Catalunya Central, people who meet the requirements will be treated at CUAP Bages and in the Emergency Room of the Hospital Sant Bernabé de Berga.
- Study Population: People with 50 years of age or older who have had a positive COVID-19 result by PCR or rapid antigen test and who have symptoms not requiring hospitalization for less than 7 days.
- Study type: Double-blind, Randomized, Prospective Clinical Trial.
- Design: Randomized study, in which there will be two treatment groups that, in addition to the therapy prescribed by their medical professional for COVID-19, will receive either convalescent plasma or placebo. Assignment to one group or the other will be randomized. It is also a double-blind study in which neither the research team nor the participant will know to which group the latter belongs.
- Methods: The two treatments (convalescent plasma and placebo) will be administered by intravenous infusion of about 30-40 minutes of duration in a hospital setting. Administration will be performed on the first day of the study, after checking blood group compatibility.
Objectives of the Study:
Principal Objective: To evaluate the efficacy and safety of convalescent plasma treatment in people over 50 years of age with mild to moderate COVID-19 disease who are not hospitalized.
More about this Study:
Scientific context: Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by the SARS-CoV-2 virus. The uncontrolled spread of the SARS-CoV-2 coronavirus has generated an unprecedented health emergency that requires the urgent development of new strategies to protect the population, mainly those most at risk.
Convalescent plasma is given by persons who have passed COVID-19 and contain antibodies against the SARS-CoV-2 virus.
Plasma therapy has been used to treat many conditions and is safe. Convalescent plasma therapy could be very useful for the entire population, mainly for those who are older or have risk factors for developing complications of COVID-19.
Other Clinical Trials:
Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.
Using a mouthwash containing β-cyclodextrin and citrox (bioflavonoids) (CDCM), available in pharmacies, helps reduce the SARS-CoV-2 viral load in saliva.
This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer’s COVID vaccine in children under 12 years of age.
The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.
Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.
This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.
Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.